Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis - Pub
6 hours ago
- #refractory
- #selinexor
- #multiple myeloma
- SVd regimen (selinexor, bortezomib, dexamethasone) shows efficacy in penta-refractory multiple myeloma after BCMA- and GPRC5D-targeted therapy failure.
- In a retrospective multicenter analysis of 18 heavily pretreated patients, overall response rate was 61%, median progression-free survival 4.3 months.
- SVd demonstrated activity in extramedullary disease and allowed successful transition to subsequent CAR T-cell therapy in some cases, with manageable toxicity.